CN1554351A - 包含活性维生素d化合物的药物组合制剂及其应用 - Google Patents
包含活性维生素d化合物的药物组合制剂及其应用 Download PDFInfo
- Publication number
- CN1554351A CN1554351A CNA2004100475609A CN200410047560A CN1554351A CN 1554351 A CN1554351 A CN 1554351A CN A2004100475609 A CNA2004100475609 A CN A2004100475609A CN 200410047560 A CN200410047560 A CN 200410047560A CN 1554351 A CN1554351 A CN 1554351A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- dihydroxyvitamin
- medicament
- anticarcinogen
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims description 7
- 150000001875 compounds Chemical class 0.000 title description 43
- 239000011782 vitamin Substances 0.000 title description 14
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 title 1
- 239000002131 composite material Substances 0.000 title 1
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 51
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 51
- 239000011710 vitamin D Substances 0.000 claims abstract description 51
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 51
- 229940046008 vitamin d Drugs 0.000 claims abstract description 51
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 37
- 230000024245 cell differentiation Effects 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims description 52
- -1 vitamin D compounds Chemical class 0.000 claims description 32
- 239000003005 anticarcinogenic agent Substances 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 20
- 238000011282 treatment Methods 0.000 claims description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 239000003098 androgen Substances 0.000 claims description 15
- 239000003112 inhibitor Substances 0.000 claims description 14
- HKXBNHCUPKIYDM-CGMHZMFXSA-N doxercalciferol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C HKXBNHCUPKIYDM-CGMHZMFXSA-N 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- 230000004663 cell proliferation Effects 0.000 claims description 5
- 239000000328 estrogen antagonist Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- NEETXMRNUNEBRH-GOTXBORWSA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-1-[(2r,5s)-5,6-dimethylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CC[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C NEETXMRNUNEBRH-GOTXBORWSA-N 0.000 claims description 4
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 claims description 4
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims description 4
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 4
- 229930195573 Amycin Natural products 0.000 claims description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 4
- 229930192392 Mitomycin Natural products 0.000 claims description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 4
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 claims description 4
- 230000002280 anti-androgenic effect Effects 0.000 claims description 4
- 239000000051 antiandrogen Substances 0.000 claims description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 4
- 229960004316 cisplatin Drugs 0.000 claims description 4
- 229960000975 daunorubicin Drugs 0.000 claims description 4
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 4
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 claims description 4
- 229960001842 estramustine Drugs 0.000 claims description 4
- 229960002949 fluorouracil Drugs 0.000 claims description 4
- 239000002434 gonadorelin derivative Substances 0.000 claims description 4
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 4
- 229960001924 melphalan Drugs 0.000 claims description 4
- 229960000485 methotrexate Drugs 0.000 claims description 4
- 229960004857 mitomycin Drugs 0.000 claims description 4
- 229960004694 prednimustine Drugs 0.000 claims description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 230000002159 abnormal effect Effects 0.000 claims description 2
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical class C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 23
- 201000010099 disease Diseases 0.000 abstract description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 19
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract description 13
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract description 13
- 238000002560 therapeutic procedure Methods 0.000 abstract description 12
- 208000037147 Hypercalcaemia Diseases 0.000 abstract description 9
- 230000000148 hypercalcaemia Effects 0.000 abstract description 9
- 208000030915 hypercalcemia disease Diseases 0.000 abstract description 9
- 210000002307 prostate Anatomy 0.000 abstract description 9
- 206010060862 Prostate cancer Diseases 0.000 abstract description 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract description 7
- 206010020590 Hypercalciuria Diseases 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 230000003463 hyperproliferative effect Effects 0.000 abstract description 3
- 230000001413 cellular effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 41
- 108050000156 vitamin D receptors Proteins 0.000 description 23
- 102000009310 vitamin D receptors Human genes 0.000 description 22
- 238000000034 method Methods 0.000 description 20
- 201000001514 prostate carcinoma Diseases 0.000 description 20
- 239000001963 growth medium Substances 0.000 description 17
- 102000018997 Growth Hormone Human genes 0.000 description 14
- 108010051696 Growth Hormone Proteins 0.000 description 14
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 14
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 14
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 14
- 239000000122 growth hormone Substances 0.000 description 14
- 238000011160 research Methods 0.000 description 13
- 229940088594 vitamin Drugs 0.000 description 12
- 229930003231 vitamin Natural products 0.000 description 12
- 235000013343 vitamin Nutrition 0.000 description 12
- 150000003722 vitamin derivatives Chemical class 0.000 description 12
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 10
- 239000011575 calcium Substances 0.000 description 10
- 229910052791 calcium Inorganic materials 0.000 description 10
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 230000002062 proliferating effect Effects 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 7
- 210000000988 bone and bone Anatomy 0.000 description 7
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 7
- 229960000452 diethylstilbestrol Drugs 0.000 description 7
- 229940011871 estrogen Drugs 0.000 description 7
- 239000000262 estrogen Substances 0.000 description 7
- 229940088597 hormone Drugs 0.000 description 7
- 239000005556 hormone Substances 0.000 description 7
- 229960003604 testosterone Drugs 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 125000002252 acyl group Chemical group 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 125000001183 hydrocarbyl group Chemical group 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000003211 malignant effect Effects 0.000 description 5
- 231100000682 maximum tolerated dose Toxicity 0.000 description 5
- 206010061289 metastatic neoplasm Diseases 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 206010006002 Bone pain Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 230000001028 anti-proliverative effect Effects 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000011612 calcitriol Substances 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 3
- 238000001794 hormone therapy Methods 0.000 description 3
- 230000000640 hydroxylating effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000002398 materia medica Substances 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229940122361 Bisphosphonate Drugs 0.000 description 2
- 206010065687 Bone loss Diseases 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108010081690 Pertussis Toxin Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 150000004663 bisphosphonates Chemical class 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 229940035811 conjugated estrogen Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 description 2
- 125000003709 fluoroalkyl group Chemical group 0.000 description 2
- 229960002074 flutamide Drugs 0.000 description 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 230000001456 gonadotroph Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003652 hormone inhibitor Substances 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000000505 pernicious effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000002769 thiazolinyl group Chemical group 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 101000904177 Clupea pallasii Gonadoliberin-1 Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 244000287680 Garcinia dulcis Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 208000003837 Second Primary Neoplasms Diseases 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 230000035563 calcemia Effects 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 230000003913 calcium metabolism Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 201000005991 hyperphosphatemia Diseases 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- WGJJROVFWIXTPA-OALUTQOASA-N prostanoic acid Chemical compound CCCCCCCC[C@H]1CCC[C@@H]1CCCCCCC(O)=O WGJJROVFWIXTPA-OALUTQOASA-N 0.000 description 1
- 210000005267 prostate cell Anatomy 0.000 description 1
- 238000011471 prostatectomy Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/16—Fluorine compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/22—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/781,910 | 1996-12-30 | ||
| US08/781,910 US5763429A (en) | 1993-09-10 | 1996-12-30 | Method of treating prostatic diseases using active vitamin D analogues |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB971819742A Division CN1158081C (zh) | 1996-12-30 | 1997-12-10 | 包含活性维生素d化合物的药物组合物及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1554351A true CN1554351A (zh) | 2004-12-15 |
Family
ID=25124345
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2004100475609A Pending CN1554351A (zh) | 1996-12-30 | 1997-12-10 | 包含活性维生素d化合物的药物组合制剂及其应用 |
| CNB971819742A Expired - Fee Related CN1158081C (zh) | 1996-12-30 | 1997-12-10 | 包含活性维生素d化合物的药物组合物及其应用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB971819742A Expired - Fee Related CN1158081C (zh) | 1996-12-30 | 1997-12-10 | 包含活性维生素d化合物的药物组合物及其应用 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US5763429A (enExample) |
| EP (1) | EP0948334B1 (enExample) |
| JP (1) | JP2001511768A (enExample) |
| KR (1) | KR20000062403A (enExample) |
| CN (2) | CN1554351A (enExample) |
| AT (1) | ATE347366T1 (enExample) |
| AU (1) | AU723835B2 (enExample) |
| BR (1) | BR9713663A (enExample) |
| CA (1) | CA2276606C (enExample) |
| DE (1) | DE69737066T2 (enExample) |
| HU (1) | HUP0000558A3 (enExample) |
| NZ (1) | NZ336508A (enExample) |
| PL (1) | PL334393A1 (enExample) |
| WO (1) | WO1998029123A1 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040009958A1 (en) * | 1991-01-08 | 2004-01-15 | Bone Care International, Inc. | Methods for preparation and use of 1alpha,24(S)-dihydroxyvitamin D2 |
| US6538037B2 (en) | 1991-01-08 | 2003-03-25 | Bone Care International, Inc. | Methods for preparation and use of 1α,24(S)-dihydroxyvitamin D2 |
| US5763429A (en) * | 1993-09-10 | 1998-06-09 | Bone Care International, Inc. | Method of treating prostatic diseases using active vitamin D analogues |
| US20040043971A1 (en) * | 1995-04-03 | 2004-03-04 | Bone Care International, Inc. | Method of treating and preventing hyperparathyroidism with active vitamin D analogs |
| US20020183288A1 (en) * | 1995-04-03 | 2002-12-05 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
| US6242434B1 (en) * | 1997-08-08 | 2001-06-05 | Bone Care International, Inc. | 24-hydroxyvitamin D, analogs and uses thereof |
| US6503893B2 (en) | 1996-12-30 | 2003-01-07 | Bone Care International, Inc. | Method of treating hyperproliferative diseases using active vitamin D analogues |
| US6566353B2 (en) | 1996-12-30 | 2003-05-20 | Bone Care International, Inc. | Method of treating malignancy associated hypercalcemia using active vitamin D analogues |
| US6573256B2 (en) | 1996-12-30 | 2003-06-03 | Bone Care International, Inc. | Method of inhibiting angiogenesis using active vitamin D analogues |
| US20020128240A1 (en) * | 1996-12-30 | 2002-09-12 | Bone Care International, Inc. | Treatment of hyperproliferative diseases using active vitamin D analogues |
| CA2279590A1 (en) * | 1997-02-13 | 1998-08-20 | Bone Care International, Inc. | Targeted therapeutic delivery of vitamin d compounds |
| US20030129194A1 (en) * | 1997-02-13 | 2003-07-10 | Bone Care International, Inc. | Targeted therapeutic delivery of vitamin D compounds |
| US6900191B1 (en) * | 1997-02-25 | 2005-05-31 | Oncquest, Inc. | 1α-Hydroxyvitamin D5, its synthesis and use in cancer prevention |
| US6605599B1 (en) * | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
| US6087350A (en) * | 1997-08-29 | 2000-07-11 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Use of pretreatment chemicals to enhance efficacy of cytotoxic agents |
| US6043385A (en) * | 1997-12-16 | 2000-03-28 | Hoffman-La Roche Inc. | Vitamin D derivatives |
| CN1301298A (zh) * | 1998-03-25 | 2001-06-27 | 卡坦诺根公司 | 用于预防和治疗癌症的方法 |
| ES2368824T3 (es) | 1998-03-27 | 2011-11-22 | Oregon Health & Science University | Vitamina d y sus análogos en el tratamiento de tumores y otros desórdenes hiperproliferativos. |
| EP2070911A2 (en) | 2000-07-18 | 2009-06-17 | Bone Care International, Inc. | Stabilized 1Alpha-Hydroxy vitamin D |
| US20030134324A1 (en) * | 2000-08-07 | 2003-07-17 | Munger William E. | Identifying drugs for and diagnosis of Benign Prostatic Hyperplasia using gene expression profiles |
| US7321830B2 (en) * | 2000-08-07 | 2008-01-22 | Gene Logic, Inc. | Identifying drugs for and diagnosis of benign prostatic hyperplasia using gene expression profiles |
| WO2002039996A2 (en) * | 2000-11-16 | 2002-05-23 | Pharmacia & Up John Company | Combined therapy against tumors comprising estramustine phosphate and lhrh agonists or antagonists |
| KR20050044655A (ko) * | 2001-12-03 | 2005-05-12 | 노바세아, 인크. | 활성 비타민 ｄ 화합물을 함유하는 약제학적 조성물 |
| US7148211B2 (en) * | 2002-09-18 | 2006-12-12 | Genzyme Corporation | Formulation for lipophilic agents |
| US20040053895A1 (en) * | 2002-09-18 | 2004-03-18 | Bone Care International, Inc. | Multi-use vessels for vitamin D formulations |
| AR044732A1 (es) * | 2002-11-08 | 2005-10-05 | H P B S A | Composicion farmaceutica para el tratamiento medico de la hiperplasia benigan de la prostata, su metodo de preparacion y su aplicacion terapeutica |
| AU2003295773A1 (en) * | 2002-11-21 | 2004-06-18 | Novacea, Inc. | Treatment of liver disease with active vitamin d compounds |
| US20050026877A1 (en) * | 2002-12-03 | 2005-02-03 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
| US20050020546A1 (en) * | 2003-06-11 | 2005-01-27 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
| AU2004247109A1 (en) * | 2003-06-11 | 2004-12-23 | Novacea, Inc | Treatment of cancer with active vitamin D compounds in combination with radiotherapeutic agents and treatments |
| WO2005016872A1 (en) * | 2003-06-11 | 2005-02-24 | Novacea, Inc. | Treatment of lung cancer with active vitamin d compounds in combination with other treatments |
| CA2528378A1 (en) * | 2003-06-11 | 2004-12-23 | Novacea, Inc. | Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents |
| GB0320806D0 (en) * | 2003-09-05 | 2003-10-08 | Astrazeneca Ab | Therapeutic treatment |
| PT103177A (pt) * | 2003-09-24 | 2005-03-31 | Bioxell Spa | 1-alfa-fluoro-25-hidroxi-16,23e-dieno-26,27-bis-homo-20-epi-colecalciferol, seus sais ou esteres e sua utilizacao no fabrico de medicamentos |
| BRPI0404050A (pt) * | 2003-09-24 | 2005-06-14 | Bioxell Spa | Uso de um composto ou de um seu sal ou éster farmaceuticamente aceitável, formulação farmacêutica, formulação acondicionada, composto, e, método para prevenir e/ou tratar hiperplasia benigna da próstata em pacientes em necessidade de tal prevenção ou tratamento |
| AU2004275845A1 (en) * | 2003-09-24 | 2005-04-07 | Bioxell, S.P.A. | Methods for treating bladder dysfunction |
| WO2005097128A1 (en) * | 2004-03-30 | 2005-10-20 | Novacea, Inc. | 1,4-bis-n-oxide azaanthracenediones and the use thereof |
| WO2005117542A2 (en) * | 2004-05-10 | 2005-12-15 | Novacea, Inc. | Treatment of pancreatic cancer with active vitamin d compounds in combination with other treatments |
| US20060003950A1 (en) * | 2004-06-30 | 2006-01-05 | Bone Care International, Inc. | Method of treating prostatic diseases using a combination of vitamin D analogues and other agents |
| US7094775B2 (en) * | 2004-06-30 | 2006-08-22 | Bone Care International, Llc | Method of treating breast cancer using a combination of vitamin D analogues and other agents |
| WO2006035075A1 (en) * | 2004-09-30 | 2006-04-06 | Bioxell Spa | Use of vitamin d compounds for the prevention or treatment of chronic prostatitis |
| US20080293647A1 (en) * | 2004-11-12 | 2008-11-27 | Luciano Adorini | Combined Use Of Vitamin D Derivatives And Anti-Proliferative Agents For Treating Bladder Cancer |
| US20060105583A1 (en) * | 2004-11-17 | 2006-05-18 | Asm Japan K.K. | Formation technology of nano-particle films having low dielectric constant |
| GB0425854D0 (en) * | 2004-11-25 | 2004-12-29 | Astrazeneca Ab | Therapeutic treatment |
| US9579238B2 (en) | 2005-02-17 | 2017-02-28 | The Procter & Gamble Company | Sanitary napkins capable of taking complex three-dimensional shape in use |
| US20100009949A1 (en) * | 2006-03-24 | 2010-01-14 | Bioxell S.P.A. | Novel method |
| KR200439485Y1 (ko) * | 2006-10-31 | 2008-04-15 | 한국전력공사 | 중수로내 원자로관 처짐도 검사 장비용 연장관 |
| CN114269348A (zh) * | 2019-08-22 | 2022-04-01 | 工业技术和生物技术公司 | 用于治疗和预防癌症的激素d(维生素d)及其衍生物 |
Family Cites Families (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2383446A (en) * | 1941-06-04 | 1945-08-28 | Du Pont | Antirachitic materials and processes for their production |
| US3697559A (en) * | 1971-02-25 | 1972-10-10 | Wisconsin Alumni Res Found | 1,25-dihydroxycholecalciferol |
| US3741996A (en) * | 1971-12-02 | 1973-06-26 | Wisconsin Alumni Res Found | 1{60 -hydroxycholecalciferol |
| US4670190A (en) * | 1973-01-10 | 1987-06-02 | Hesse Robert H | 1-α-hydroxy vitamin D compounds and process for preparing same |
| US3907843A (en) * | 1974-06-14 | 1975-09-23 | Wisconsin Alumni Res Found | 1{60 -Hydroxyergocalciferol and processes for preparing same |
| US4202829A (en) * | 1978-01-05 | 1980-05-13 | Wisconsin Alumni Research Foundation | Process for preparing 1α-hydroxylated compounds |
| FR2446278A2 (en) * | 1978-01-16 | 1980-08-08 | Wisconsin Alumni Res Found | 1-alpha-hydroxy-vitamin=D deriv. preparation - by solvolysis of 1-alpha-hydroxy-cyclo-vitamin=D using carboxylic acid e.g. acetic to give 3 O-acyl cpd. which is hydrolysed or reduced |
| US4195027A (en) * | 1978-01-16 | 1980-03-25 | Wisconsin Alumni Research Foundation | Process for preparing 1α-hydroxylated compounds |
| US4260549A (en) * | 1979-05-21 | 1981-04-07 | Wisconsin Alumni Research Foundation | Process for preparing 1α-hydroxylated compounds |
| US4160803A (en) * | 1978-03-23 | 1979-07-10 | Corning Glass Works | Self packaged test kit |
| US4225596A (en) * | 1978-10-13 | 1980-09-30 | Wisconsin Alumni Research Foundation | Method for treating calcium imbalance and improving calcium absorption in mammals |
| US4234495A (en) * | 1979-09-10 | 1980-11-18 | Wisconsin Alumni Research Foundation | Process for preparing 1α-hydroxyvitamin D compounds from 1α-hydroxy-3,5-cyclovitamin D compounds |
| US4362710A (en) * | 1980-07-04 | 1982-12-07 | Nissan Gosei Kogyo Co., Ltd. | Feeds for baby pigs, process for preparing the same and method of breeding baby pigs |
| JPS57149224A (en) * | 1981-03-13 | 1982-09-14 | Chugai Pharmaceut Co Ltd | Tumor-suppressing agent |
| US4508651A (en) * | 1983-03-21 | 1985-04-02 | Hoffmann-La Roche Inc. | Synthesis of 1α,25-dihydroxyergocalciferol |
| NL193245C (nl) * | 1983-05-09 | 1999-04-02 | Wisconsin Alumni Res Found | Aan 1Ó,25-dihydroxyvitamine D2 verwante verbinding en farmaceutisch preparaat met een het calciummetabolisme regulerende werking dat een dergelijke verbinding bevat. |
| US4689180A (en) * | 1984-01-30 | 1987-08-25 | Wisconsin Alumni Research Foundation | 1α,25-dihydroxy-22Z-dehydroxyvitamin D compound |
| US4588716A (en) * | 1984-05-04 | 1986-05-13 | Wisconsin Alumni Research Foundation | Method for treating metabolic bone disease in mammals |
| US4554106A (en) * | 1984-11-01 | 1985-11-19 | Wisconsin Alumni Research Foundation | Method for preparing 1α-hydroxyvitamin D compounds |
| US4555364A (en) * | 1984-11-01 | 1985-11-26 | Wisconsin Alumni Research Foundation | Method for preparing 1-hydroxyvitamin D compounds |
| US4728643A (en) * | 1984-11-02 | 1988-03-01 | The General Hospital Corporation | Method of treating psoriasis |
| US5037816A (en) * | 1984-11-02 | 1991-08-06 | The General Hospital Corporation | Method of treating psoriasis |
| US4717721A (en) * | 1985-05-30 | 1988-01-05 | Howard W. Bremer | Sidechain homo-vitamin D compounds with preferential anti-cancer activity |
| US4661294A (en) * | 1985-03-18 | 1987-04-28 | The General Hospital Corporation | Biologically active 1-thio derivatives of vitamin D |
| IL78342A (en) * | 1985-04-04 | 1991-06-10 | Gen Hospital Corp | Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof |
| US4686104A (en) * | 1985-04-30 | 1987-08-11 | Sloan-Kettering Institute For Cancer Research | Methods of treating bone disorders |
| EP0227826B1 (en) * | 1985-08-02 | 1989-10-25 | Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) | Novel vitamin d analogues |
| US5554386A (en) * | 1986-07-03 | 1996-09-10 | Advanced Magnetics, Inc. | Delivery of therapeutic agents to receptors using polysaccharides |
| US5338532A (en) * | 1986-08-18 | 1994-08-16 | The Dow Chemical Company | Starburst conjugates |
| US5527524A (en) * | 1986-08-18 | 1996-06-18 | The Dow Chemical Company | Dense star polymer conjugates |
| US4833125A (en) | 1986-12-05 | 1989-05-23 | The General Hospital Corporation | Method of increasing bone mass |
| US4902481A (en) * | 1987-12-11 | 1990-02-20 | Millipore Corporation | Multi-well filtration test apparatus |
| US5087619A (en) * | 1988-01-20 | 1992-02-11 | Hoffman-La Roche Inc. | Vitamin D3 analogs |
| US5145846A (en) * | 1988-01-20 | 1992-09-08 | Hoffmann-La Roche Inc. | Vitamin D3 analogs |
| US5232836A (en) * | 1988-05-04 | 1993-08-03 | Ire-Medgenix S.A. | Vitamin D derivatives: therapeutic applications and applications to assays of metabolites of vitamin D |
| JP2550391B2 (ja) * | 1988-06-30 | 1996-11-06 | 日清製粉株式会社 | １β−ヒドロキシビタミンＤ▲下２▼およびＤ▲下３▼の製造方法 |
| CA1341408C (en) * | 1988-08-02 | 2002-12-10 | Charles W. Bishop | Method for treating and preventing loss of bone mass |
| US5104864A (en) * | 1988-08-02 | 1992-04-14 | Bone Care International, Inc. | Method for treating and preventing loss of bone mass |
| US5602116A (en) * | 1988-08-02 | 1997-02-11 | Bone Care International, Inc. | Method for treating and preventing secondary hyperparathyroidism |
| US5098899A (en) * | 1989-03-06 | 1992-03-24 | Trustees Of Boston University | Method for therapeutically treating psoriatic arthritis using vitamin D analogues and metabolites |
| US5321018A (en) * | 1989-03-09 | 1994-06-14 | Wisconsin Alumni Research Foundation | Use of 1α-hydroxylated-19-nor-vitamin D compounds to treat psoriasis |
| CA1333616C (en) * | 1989-03-09 | 1994-12-20 | Hector F. Deluca | 19-nor-vitamin d compounds |
| US5372996A (en) | 1989-03-10 | 1994-12-13 | Endorecherche, Inc. | Method of treatment of androgen-related diseases |
| US4948789A (en) * | 1989-03-28 | 1990-08-14 | Chugai Seiyaku Kabushiki Kaisha | Suppression of parathyroid hormone synthesis and secretion |
| JP2645130B2 (ja) * | 1989-03-31 | 1997-08-25 | 日清製粉株式会社 | ステロイド誘導体 |
| GB2229921B (en) * | 1989-04-05 | 1992-12-16 | Chugai Pharmaceutical Co Ltd | Treatment for hyperparathyroidism with use of vitamin d derivatives |
| US5219528A (en) * | 1989-07-28 | 1993-06-15 | Pierce Chemical Company | Apparatus for rapid immunoassays |
| US5194248A (en) * | 1990-06-21 | 1993-03-16 | Trustees Of Boston University | Compositions comprising vitamin D analog precursors and the use thereof |
| US5141719A (en) * | 1990-07-18 | 1992-08-25 | Bio-Rad Laboratories, Inc. | Multi-sample filtration plate assembly |
| US5763428A (en) * | 1990-09-21 | 1998-06-09 | Bone Care International, Inc. | Methods of treating skin disorders with novel 1a-hydroxy vitamin D4 compounds and derivatives thereof |
| WO1992005130A1 (en) * | 1990-09-21 | 1992-04-02 | Lunar Corporation | NOVEL 1α-HYDROXY VITAMIN D4 AND NOVEL INTERMEDIATES AND ANALOGUES |
| US5798345A (en) * | 1990-09-21 | 1998-08-25 | Bone Care International, Inc. | Method of inhibiting the hyperproliferation of malignant cells |
| US6025346A (en) * | 1990-09-21 | 2000-02-15 | Bone Care International, Inc. | 1α-hydroxy vitamin D4 and novel intermediates and analogues |
| DE69229103T2 (de) * | 1991-01-08 | 1999-10-14 | Bone Care International Inc. | Verfahren zur herstellung und verwendung von 1alpha,24-dihydroxy vitamin-d2 |
| US6538037B2 (en) * | 1991-01-08 | 2003-03-25 | Bone Care International, Inc. | Methods for preparation and use of 1α,24(S)-dihydroxyvitamin D2 |
| US5789397A (en) * | 1991-01-08 | 1998-08-04 | Bone Care International, Inc. | Methods for preparation and use of 1A,24(S)-dihydroxy vitamin D2 |
| EP0503630B1 (en) * | 1991-03-13 | 1995-12-27 | Kuraray Co., Ltd. | Cyclohexanetriol derivatives |
| US5417923A (en) * | 1991-04-24 | 1995-05-23 | Pfizer Inc. | Assay tray assembly |
| AU650751B2 (en) * | 1991-05-28 | 1994-06-30 | Wisconsin Alumni Research Foundation | Novel synthesis of 19-nor vitamin D compounds |
| CA2109958C (en) * | 1991-05-28 | 1997-06-10 | Mark Benson Andon | Calcium, trace mineral, vitamin d and drug therapy combinations |
| EP0521550B1 (en) * | 1991-07-05 | 1996-09-18 | Duphar International Research B.V | Vitamin D compound, method of preparing this compound and intermediate therefor |
| US5205989A (en) * | 1991-09-18 | 1993-04-27 | Minnesota Mining And Manufacturing Company | Multi-well filtration apparatus |
| DE69125836T2 (de) | 1991-11-14 | 1997-12-18 | Quantum Corp | Spindel- und Nabenausrüstung |
| WO1993014763A1 (en) | 1992-01-29 | 1993-08-05 | Lunar Corporation | 1α-HYDROXY-24-EPI-VITAMIN D¿4? |
| EP0562497A1 (en) * | 1992-03-27 | 1993-09-29 | Nisshin Flour Milling Co., Ltd. | 1 alpha-hydroxy vitamins D7 and D4' processes for the preparation thereof and pharmaceutical compositions |
| US6113946A (en) * | 1992-04-03 | 2000-09-05 | The Regents Of The University Of California | Self-assembling polynucleotide delivery system comprising dendrimer polycations |
| ATE211387T1 (de) * | 1992-06-22 | 2002-01-15 | Bone Care Int Inc | Oral 1alpha-hydroxyprevitamin d |
| US5795882A (en) * | 1992-06-22 | 1998-08-18 | Bone Care International, Inc. | Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations |
| US5753638A (en) * | 1992-10-07 | 1998-05-19 | Hoffmann-La Roche Inc. | Method of treating hyperproliferative skin disease with Vitamin D3 fluorinated analogs |
| CA2096105A1 (en) * | 1992-10-07 | 1994-04-08 | Enrico Giuseppe Baggiolini (Deceased) | Vitamin d3 fluorinated analogs |
| US5350745A (en) | 1993-01-29 | 1994-09-27 | Lunar Corporation | Treatment of myocardial failure |
| ATE195431T1 (de) * | 1993-09-01 | 2000-09-15 | Teijin Ltd | Emulsion auf der basis von 1-alpha,24-dihydroxy- vitamin d3 |
| US5763429A (en) * | 1993-09-10 | 1998-06-09 | Bone Care International, Inc. | Method of treating prostatic diseases using active vitamin D analogues |
| US6103709A (en) * | 1993-12-23 | 2000-08-15 | The Regents Of The University Of California | Therapeutically effective 1α,25-dihydroxyvitamin D3 analogs and methods for treatment of vitamin D diseases |
| DK0664287T3 (da) * | 1994-01-20 | 1999-04-19 | Duphar Int Res | Vitamin D-forbindelser og fremgangsmåde til fremstilling af disse |
| US5597575A (en) * | 1994-06-06 | 1997-01-28 | Breitbarth; Richard | Composition for stimulating and inducing hair growth |
| US5739271A (en) * | 1995-06-07 | 1998-04-14 | Gen-Probe Incorporated | Thiocationic lipids |
| US6221911B1 (en) * | 1995-06-07 | 2001-04-24 | Karo Bio Ab | Uses for thyroid hormone compounds or thyroid hormone-like compounds |
| JPH11514999A (ja) * | 1995-10-10 | 1999-12-21 | ストルーブ，マリリン | ビタミンｄおよびその誘導体による掻痒症治療 |
| PT771789E (pt) * | 1995-10-30 | 2000-05-31 | Hoffmann La Roche | 1 alfa 26-di-hidroxi-d-homo-vitamina d3 |
| AU710931B2 (en) * | 1996-02-28 | 1999-09-30 | Sumitomo Pharmaceuticals Company, Limited | Crystalline vitamin D derivative |
| DE19619036A1 (de) * | 1996-04-30 | 1997-11-13 | Schering Ag | Neue Vitamin D-Derivate mit carbo- oder heterocyclischen Substituenten an C-25, Verfahren zu ihrer Herstellung und die Verwendung zur Herstellung von Arzneimitteln |
| US6573256B2 (en) * | 1996-12-30 | 2003-06-03 | Bone Care International, Inc. | Method of inhibiting angiogenesis using active vitamin D analogues |
| US6503893B2 (en) * | 1996-12-30 | 2003-01-07 | Bone Care International, Inc. | Method of treating hyperproliferative diseases using active vitamin D analogues |
| US6566353B2 (en) * | 1996-12-30 | 2003-05-20 | Bone Care International, Inc. | Method of treating malignancy associated hypercalcemia using active vitamin D analogues |
| US6372234B1 (en) * | 1997-05-27 | 2002-04-16 | Sembiosys Genetics Inc. | Products for topical applications comprising oil bodies |
| US6599513B2 (en) * | 1997-05-27 | 2003-07-29 | Sembiosys Genetics Inc. | Products for topical applications comprising oil bodies |
| US6087350A (en) * | 1997-08-29 | 2000-07-11 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Use of pretreatment chemicals to enhance efficacy of cytotoxic agents |
| ES2368824T3 (es) * | 1998-03-27 | 2011-11-22 | Oregon Health & Science University | Vitamina d y sus análogos en el tratamiento de tumores y otros desórdenes hiperproliferativos. |
| US6114317A (en) * | 1998-05-21 | 2000-09-05 | Wisconsin Alumni Research Foundation | Method of locking 1α-OH of vitamin D compounds in axial orientation |
| US6552009B2 (en) * | 1998-07-16 | 2003-04-22 | Gentrix Llc | Compositions and methods of treating abnormal cell proliferation |
| US20010002396A1 (en) * | 1998-07-16 | 2001-05-31 | Charles Achkar | Compositions and methods of treating skin conditions |
| US6218430B1 (en) * | 1998-08-24 | 2001-04-17 | Ligand Pharmaceuticals Incorporated | Vitamin D3 mimics |
| AU758792B2 (en) * | 1998-10-23 | 2003-03-27 | Teijin Limited | Vitamin D3 derivatives and remedies for inflammatory respiratory diseases containing the same |
| US6524594B1 (en) * | 1999-06-23 | 2003-02-25 | Johnson & Johnson Consumer Companies, Inc. | Foaming oil gel compositions |
| DE60014393T2 (de) * | 1999-07-16 | 2006-02-16 | Leo Pharma A/S | Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha |
| US6566554B1 (en) * | 1999-07-16 | 2003-05-20 | Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) | Aminobenzophenones as inhibitors of IL-1β and TNF-α |
| US6369098B1 (en) * | 1999-10-05 | 2002-04-09 | Bethesda Pharmaceuticals, Inc. | Dithiolane derivatives |
| CA2393312C (en) * | 1999-12-06 | 2011-07-12 | Leo Pharma A/S | Aminobenzophenones as inhibitors of il-1.beta. and tnf-.alpha. |
| US6989377B2 (en) * | 1999-12-21 | 2006-01-24 | Wisconsin Alumni Research Foundation | Treating vitamin D responsive diseases |
| WO2001090074A2 (en) * | 2000-05-22 | 2001-11-29 | Leo Pharma A/S | BENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) |
| US6395784B1 (en) * | 2000-06-07 | 2002-05-28 | Bristol-Myers Squibb Company | Benzamide ligands for the thyroid receptor |
| US20030149005A1 (en) * | 2001-08-22 | 2003-08-07 | Posner Gary H. | 24-sulfur-substituted analogs of 1alpha, 25-dihydroxy vitamin D3 |
-
1996
- 1996-12-30 US US08/781,910 patent/US5763429A/en not_active Expired - Lifetime
-
1997
- 1997-12-10 EP EP97952316A patent/EP0948334B1/en not_active Expired - Lifetime
- 1997-12-10 CN CNA2004100475609A patent/CN1554351A/zh active Pending
- 1997-12-10 AU AU55956/98A patent/AU723835B2/en not_active Ceased
- 1997-12-10 BR BR9713663-8A patent/BR9713663A/pt not_active IP Right Cessation
- 1997-12-10 KR KR1019997005996A patent/KR20000062403A/ko not_active Withdrawn
- 1997-12-10 JP JP53002898A patent/JP2001511768A/ja active Pending
- 1997-12-10 PL PL97334393A patent/PL334393A1/xx unknown
- 1997-12-10 AT AT97952316T patent/ATE347366T1/de not_active IP Right Cessation
- 1997-12-10 NZ NZ336508A patent/NZ336508A/en unknown
- 1997-12-10 HU HU0000558A patent/HUP0000558A3/hu unknown
- 1997-12-10 WO PCT/US1997/022450 patent/WO1998029123A1/en not_active Ceased
- 1997-12-10 CA CA002276606A patent/CA2276606C/en not_active Expired - Fee Related
- 1997-12-10 CN CNB971819742A patent/CN1158081C/zh not_active Expired - Fee Related
- 1997-12-10 DE DE69737066T patent/DE69737066T2/de not_active Expired - Lifetime
-
1998
- 1998-02-23 US US09/596,149 patent/US6537982B1/en not_active Expired - Lifetime
-
2003
- 2003-03-25 US US10/397,136 patent/US20040023934A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX9906989A (es) | 2003-02-27 |
| KR20000062403A (ko) | 2000-10-25 |
| AU5595698A (en) | 1998-07-31 |
| US6537982B1 (en) | 2003-03-25 |
| HUP0000558A3 (en) | 2000-12-28 |
| PL334393A1 (en) | 2000-02-28 |
| BR9713663A (pt) | 2000-04-04 |
| DE69737066D1 (de) | 2007-01-18 |
| CN1158081C (zh) | 2004-07-21 |
| DE69737066T2 (de) | 2007-06-21 |
| NZ336508A (en) | 2001-08-31 |
| EP0948334A1 (en) | 1999-10-13 |
| CA2276606A1 (en) | 1998-07-09 |
| AU723835B2 (en) | 2000-09-07 |
| CN1248917A (zh) | 2000-03-29 |
| CA2276606C (en) | 2008-11-25 |
| US20040023934A1 (en) | 2004-02-05 |
| ATE347366T1 (de) | 2006-12-15 |
| JP2001511768A (ja) | 2001-08-14 |
| US5763429A (en) | 1998-06-09 |
| HUP0000558A2 (hu) | 2000-10-28 |
| EP0948334B1 (en) | 2006-12-06 |
| WO1998029123A1 (en) | 1998-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1554351A (zh) | 包含活性维生素d化合物的药物组合制剂及其应用 | |
| EP2340840B1 (en) | Pulse dose Vitamin D drug for the treatment of hyperproliferative skin diseases | |
| EP0951286B1 (en) | Method of treating prostatic diseases using delayed and/or sustained release vitamin d formulations | |
| CN100349573C (zh) | 用于亲脂性药物的制剂 | |
| CN1234366C (zh) | 活性维生素d类似物在制备用于治疗过度增殖性疾病的药物中的应用 | |
| CN1303368A (zh) | 1α－羟基－25－烯－维生素D及其类似物和应用 | |
| US6566353B2 (en) | Method of treating malignancy associated hypercalcemia using active vitamin D analogues | |
| EP0335140A1 (en) | Compositions for the treatment of osteoporosis in humans | |
| Wieder et al. | Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignancies | |
| Intragumtornchai et al. | Obstructive uropathy due to extramedullary haematopoiesis in beta thalassaemia/haemoglobin E | |
| CN101444521B (zh) | 包含阿仑膦酸钠和胆维丁的药物制剂 | |
| MXPA99006989A (es) | Metodo para el tratamiento de enfermedades prostaticas empleando analogos activos de vitamina d | |
| JPH07233062A (ja) | 人工透析患者の皮膚そう痒症治療組成物及び副甲状腺機能亢進症治療組成物 | |
| Smith et al. | Adrenalectomy for Carcinoma of Prostate | |
| Giam et al. | Ketoconazole in tinea versicolor: is ten day therapy adequate | |
| HK1030144B (en) | Method for treatment of liver tumours and pharmaceutical compositions for use therein | |
| HK1030144A1 (en) | Method for treatment of liver tumours and pharmaceutical compositions for use therein | |
| CZ235599A3 (cs) | Inhibice hyperproliferativní aktivity neoplastických nebo hyperplastických buněk lidské prostaty a farmaceutický prostředek k tomuto účelu | |
| AU2002318421A1 (en) | Method of treating malignancy associated hypercalcemia using active vitamin D analogues | |
| JP2005247871A (ja) | 人工透析患者の副甲状腺機能亢進症治療組成物 | |
| CN102614216A (zh) | 细胞功能衰退引起的骨质疏松症的联合治疗及药物组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |